Searched for
NOVARTIS GENE THERAPY
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, the company said on M...
- Novartis bets big on India; looks to grow beyond cost arbitrage to high-value innovationNovartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub ou...
- US FDA approves Novartis' gene therapy for rare muscle disorderThe US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma...
- Novartis to acquire Avidity Biosciences for about $12 billionNovartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...
- More patients can access key drugs after GST rate cutsRecent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...
- Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of opsImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...
- Rs 17 crore for a single dose: Why Zolgensma is world's most expensive medicineThe high cost of Zolgensma, a one-time gene therapy used to treat spinal muscular atrophy (SMA) in children under two, is to limited patien...
- GST exemption on medicines for rare diseases is unlikely to provide any relief to those in need: Health activistsThe recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, sa...
- Swiss drugmaker Novartis to spin off generics unit SandozThe Basel-based company, which makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension, says it wants to...
- Novartis turning to technology to manage business: Bertrand Bodson, Chief Digital OfficerSwiss drugmaker Novartis is turning to tech to deal with the pharma business in times of pandemic, as companies go virtual. Bertrand Bodson...
- ET Q&A: Need Government investments to develop cure for epidemics like Covid-19In the absence of sustained investments by government, the cure for epidemics such as Covid-19 becomes a challenge, Novartis global CEO Vas...
- Don’t foresee any disruptions due to Covid-19: Vasant Narasimhan, CEO, NovartisNovartis is one of the oldest pharma MNCs known for anti-cancer and anti-diabetic drugs. Despite the patent expiry for its popular anti-dia...
- Novartis to cut 2,200 jobs in Switzerland to boost profitabilityNovartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to ...
- There’s an explosion of data & digital opportunities in Indian healthcare: Vasant Narasimhan, CEO, NovartisOur chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.
- Novartis's $475,000 cancer breakthrough heralds new era of curesThe U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...
- Music to the ears: Can this gel repair hearing loss?While this probably won’t help people who are born deaf, scientists are hopeful it will work for patients who lost their hearing at a young...
- Novartis to test Alzheimer's drugs in patients without symptomsIn collaboration with the Banner Alzheimer's Institute, the Swiss company will study two therapies in cognitively healthy people who are at...
Load More
